Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Linde
LIN
|
+$588M |
| 2 |
Apple
AAPL
|
+$574M |
| 3 |
Illumina
ILMN
|
+$398M |
| 4 |
argenx
ARGX
|
+$306M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$250M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
+$600M |
| 2 |
AbbVie
ABBV
|
+$323M |
| 3 |
Sherwin-Williams
SHW
|
+$309M |
| 4 |
Atlassian
TEAM
|
+$250M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$241M |
Sector Composition
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.43% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
776
Kimberly-Clark
KMB
$42.5B
| $7.31M | ﹤0.01% |
54,467
-34,656
| -39% | -$4.65M |
|
777
Stem
STEM
$111M
| $7.28M | ﹤0.01% |
64,179
+734
| +1% | +$83.2K |
|
778
Olema Pharmaceuticals
OLMA
$536M
| $7.28M | ﹤0.01% |
2,085,179
-972,127
| -32% | -$3.39M |
|
779
STAAR Surgical
STAA
$1.37B
| $7.28M | ﹤0.01% |
113,774
+61,999
| +120% | +$3.96M |
|
780
Scotiabank
BNS
$79.4B
| $7.25M | ﹤0.01% |
144,110
| – | – |
|
|
BLU
781
DELISTED
BELLUS Health Inc.
BLU
| $7.17M | ﹤0.01% |
994,579
-9,282
| -0.9% | -$66.9K |
|
782
Super Micro Computer
SMCI
$26.1B
| $7.13M | ﹤0.01% |
668,790
+67,340
| +11% | +$718K |
|
783
Fox Class A
FOXA
$25.5B
| $7.1M | ﹤0.01% |
208,540
+177,803
| +578% | +$6.05M |
|
784
Dominion Energy
D
$50.7B
| $7.05M | ﹤0.01% |
126,090
-49,712
| -28% | -$2.78M |
|
785
Xometry
XMTR
$2.45B
| $7.03M | ﹤0.01% |
469,641
+1,179
| +0.3% | +$17.7K |
|
786
Ventas
VTR
$31.5B
| $6.99M | ﹤0.01% |
161,218
+81,920
| +103% | +$3.55M |
|
787
Wheaton Precious Metals
WPM
$47.9B
| $6.96M | ﹤0.01% |
144,654
-17,699
| -11% | -$851K |
|
788
Allstate
ALL
$52.7B
| $6.92M | ﹤0.01% |
62,473
+28,662
| +85% | +$3.18M |
|
789
Deutsche Bank
DB
$69.7B
| $6.88M | ﹤0.01% |
675,710
-12,547
| -2% | -$128K |
|
790
Grab
GRAB
$21.6B
| $6.85M | ﹤0.01% |
2,276,243
-1,760,170
| -44% | -$5.3M |
|
791
Takeda Pharmaceutical
TAK
$48.3B
| $6.79M | ﹤0.01% |
411,818
-15,842
| -4% | -$261K |
|
792
Doximity
DOCS
$12.9B
| $6.76M | ﹤0.01% |
208,644
+60,917
| +41% | +$1.97M |
|
793
Crinetics Pharmaceuticals
CRNX
$3.3B
| $6.69M | ﹤0.01% |
416,252
+9,988
| +2% | +$160K |
|
794
Truist Financial
TFC
$58.2B
| $6.67M | ﹤0.01% |
195,732
-109,158
| -36% | -$3.72M |
|
795
Shopify
SHOP
$185B
| $6.67M | ﹤0.01% |
139,250
-400
| -0.3% | -$19.1K |
|
796
Medpace
MEDP
$13.4B
| $6.64M | ﹤0.01% |
35,327
-31,013
| -47% | -$5.83M |
|
797
Exelon
EXC
$43.8B
| $6.58M | ﹤0.01% |
157,075
-115,861
| -42% | -$4.85M |
|
798
Viking Therapeutics
VKTX
$2.91B
| $6.52M | ﹤0.01% |
+391,136
| New | +$6.52M |
|
799
Idexx Laboratories
IDXX
$51B
| $6.51M | ﹤0.01% |
13,015
+2,547
| +24% | +$1.27M |
|
800
Leggett & Platt
LEG
$1.35B
| $6.49M | ﹤0.01% |
203,506
+87,885
| +76% | +$2.8M |
|